Company / Cost of Revenue
Bio-Rad Laboratories Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$1.2B
FY2025
5-year range
$1.2B / $1.3B
FY2021-FY2025
Trend
+4.7%
vs FY2024
Sector context
#44 of 113
Health Care
What the data says
At $1.2B, Bio-Rad Laboratories's cost of revenue ranks #70 of 113 in the Health Care sector. Cost of Revenue has fluctuated over the past 10 years, ranging from $898M in FY2017 to $1.3B in FY2021.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +3.1%.
Remained stable around $1.2B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +0.2%
- 5-Year CAGR
- +3.1%
- 10-Year CAGR
- -
Sector benchmark
#70 of 113 in Health CareTop 61% of 113This company $1.2B Sector average $11.3B
▼
-89.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.1%, indicating consistent growth.
- In FY2025, cost of revenue increased 4.7% year-over-year.
- Ranks #44 out of 113 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2021.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +4.7% |
| FY2024 | $1.2B | -4.6% |
| FY2023 | $1.2B | +0.8% |
| FY2022 | $1.2B | -3.9% |
| FY2021 | $1.3B | +20.5% |
| FY2020 | $1.1B | +1.1% |
| FY2019 | $1.1B | +13.4% |
| FY2018 | $929.7M | +3.6% |
| FY2017 | $897.8M | -9.9% |
| FY2016 | $996.5M | +11.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026